GLP-1 Compounding · Coverage Crisis
FDA dropped 30 warning letters in March 2026. Your endorsement schedule changed at renewal.
Several specialty pharmacy carriers added GLP-1 exclusions to renewal endorsement schedules in 2025-2026 — often without prominent disclosure. If you compound semaglutide or tirzepatide and your endorsement schedule contains a non-FDA-approved drug exclusion, your products liability for that revenue line is uninsured.
We help GLP-1 compounders find markets that will write the exposure with disciplined underwriting, and help you decide whether to invest in compliance posture or wind the line down.
Problem 01 · The exclusion
The endorsement schedule changed without prominent disclosure.
Many specialty pharmacy carriers added exclusions for compounded versions of FDA-approved branded drugs starting in 2025-2026. The exclusion language varies — some target only semaglutide and tirzepatide explicitly; others use broader language excluding any non-FDA-approved drug. The exclusion is often added at renewal without prominent disclosure.
Read the endorsement schedule before signing. Search for terms like "compounded," "drug shortage," "FDA-approved," and "biosimilar" in the exclusions section. If your carrier added an exclusion at renewal and you missed it, your products liability for the GLP-1 revenue line may be uninsured.
Problem 02 · The market
Markets willing to write GLP-1 are limited and pricing is moving.
Wholesale-placed specialty markets and London-market layers will write GLP-1 compounding exposure with disciplined underwriting. Expect requirements for volume caps by product, BMI distribution of patients, prescriber relationships and supervision documentation, telehealth platform controls, and prescription audit trails.
Quote validity windows are short — typically 7 to 14 days. The market posture changes faster than most renewals can move; work with a broker who is in the market weekly, not quarterly.
Problem 03 · The strategic question
Insurance is the gate. The strategic answer is yours.
The regulatory and litigation environment is volatile. The coverage problem is the immediate pain; the strategic question is whether to invest in compliance and underwriting discipline to make GLP-1 compounding insurable as a sustainable business line, or to wind it down and pivot revenue to alternative therapeutic categories.
We can help with the insurance question — we cannot make the strategic call for you. What we can do is map the underwriting requirements onto your operations and tell you what investing in insurability would cost relative to revenue concentration risk.
Frequently asked
Common questions from CDMO and CRO buyers
What changed for GLP-1 compounders in March 2026?
+
FDA issued warning letters to several large-scale GLP-1 compounding operations and reaffirmed that semaglutide and tirzepatide are no longer on the drug shortage list. The safe harbor for compounding identical or essentially-similar copies under 503A and 503B narrowed significantly.
Will my insurance cover GLP-1 claims now?
+
Depends on the carrier and endorsement. Many specialty pharmacy carriers added exclusions for non-FDA-approved drug claims starting in 2025-2026, often without prominent disclosure. Read your renewal endorsement schedule carefully.
Can I find coverage that explicitly covers GLP-1 compounding?
+
Yes, but the market is narrowing. Wholesale-placed specialty markets and London facilities will write it with disciplined underwriting — volume caps, BMI screens, telehealth controls, prescription audit trails. Pricing is moving and quote validity windows are short.
What documentation will underwriters want?
+
Volume by product, BMI distribution of patients, prescriber relationships and supervision documentation, telehealth-platform integration controls, lot tracking, and cGMP or USP 797 documentation depending on 503A vs. 503B status.
Is this a long-term sustainable line of business?
+
The regulatory and litigation environment is volatile. The coverage problem is the immediate pain; the strategic question is whether to invest in compliance and underwriting discipline to make GLP-1 compounding insurable, or to wind it down. We can help with the insurance question; the strategic question is yours.
Free coverage review